Soligenix Receives Japanese Patent for Improved Production of Synthetic Hypericin Composition
Active Ingredient in HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma
News provided by
Share this article
Share this article
PRINCETON, N.J., May 20, 2021 /PRNewswire/ Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the Japan Patent Office has allowed the patent application titled Systems and Methods for Producing Synthetic Hypericin . The allowed claims are directed to unique, proprietary methods to produce a novel, highly purified form of synthetic hypericin, and are similar to those previously allowed in the United States (U.S.). Synthetic hypericin is the active pharmaceutical ingredient in HyBryte™ (SGX301), the Company s photodynamic therapy, for which positive primary endpoint result
Share this article
Island s lead asset, ISLA-101 granted key patent from United Stated Patent & Trademark Office
Patent underpins Island s drug repurposing strategy to rapidly and efficiently develop antiviral therapies with a key focus being mosquito borne viral diseases, such as dengue fever.
Around 390 million people are infected with dengue fever each year
[1], representing a significant unmet need and opportunity.
SYDNEY, May 19, 2021 /PRNewswire/ Australian antiviral drug development company, Island Pharmaceuticals Ltd (ASX: ILA) is pleased to announce that a key patent relating to the Company s lead program, ISLA-101, has been granted by the United States Patent & Trademark Office. ISLA-101 is a drug with a very well-known safety profile, being repurposed for mosquito borne viruses.
Island Pharmaceuticals granted key patent for ISLA-101 in the United States fnarena.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fnarena.com Daily Mail and Mail on Sunday newspapers.
Soligenix Announces Recent Accomplishments And First Quarter 2021 Financial Results
News provided by
Share this article
Share this article
PRINCETON, N.J., May 17, 2021 /PRNewswire/ Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the quarter ended March 31, 2021. This year continues to be an exciting year of progress for Soligenix, stated Christopher J. Schaber, PhD, President and Chief Executive Officer of Soligenix. We recently announced presentation of clinical data from our successful pivotal Phase 3 FLASH (Fluorescent Light Activated Synthetic Hypericin) clinical trial for HyBryte™ (SGX301) in the treatment of cutaneous T-cell lymphoma (CTCL) at both the American Academy of Dermatology, where HyBryte™ was designated Top 12 late-breaking
Updated Business Strategy Focused on Small Molecule Therapeutics Kedrion to acquire, for a total of USD 17M, 2 plasma collection centers and an option to.